Protocol 120511
We will conduct a systematic review in accordance with the recommendations from the Cochrane collaborations and the PRISMA statement. We will include only randomized controlled trials with a minimum of 100 adult diabetic patients, and a mean follow-up of at least 12 months. There will be no restrictions regarding comorbidity or overall cardiovascular risk. Both hypertensive and normotensive patients will be accepted.
Three classes of interventions will be considered. 1) Trials comparing any blood pressure level with placebo. 2) Trials comparing any two, or more, blood pressure levels. 3) Trials evaluating specific drug doses, independent of pressure goals. Trials with combined interventions will be excluded.
Primary end points will be all cause mortality, myocardial infarction, stroke, congestive heart failure, end-stage renal disease, amputation and blindness. As secondary end points, cardiovascular and non-cardiovascular mortality will be used.
CENTRAL will be searched using MeSH terms "antihypertensive agent" and "blood pressure" combined. MEDLINE will be searched in accordance with the Cochrane Highly Sensitive Search Strategy, sensitivitymaximizing version, EMBASE according to Wong et al, -06, and their "small drop in sensitivity with a substantive gain in specificity" search strategy. Also BIOSIS will be searched for relevant conference proceedings, using the same strategy as for CENTRAL. Results from the above searches will be merged to remove duplicate records of the same publications. M.B. will review titles of all publications retrieved from this search. All relevant abstracts will be examined by M.B. and B.C to identify potentially relevant trials. The reference lists of relevant systematic reviews and guidelines will be browsed to identify any trial not identified in our own search. Also authors of relevant publications will be contacted, to reveal any unpublished material. M.B and B.C will then, independently, examine the potentially relevant publications in detail to make the final decision on study inclusion. This decision will be based on the trials meeting the inclusion criteria. Any disagreements will be resolved by discussion. Both reviewers will extract data into specially designed data collection forms independently. These forms will include data on all outcomes defined above and information permitting risk of bias evaluation according to the below.
Risk of bias will be assessed using the Cochrane Collaboration´s tool for assessing risk of bias. This tool take into consideration six domains, 1) sequence generation, 2) allocation concealment, 3) blinding, 4) incomplete outcome data, 5) selective outcome reporting, and 6) other sources of bias, including early stop and baseline imbalance.
Analysis will be based upon risk ratio for each of the outcomes measured. We will analyse the outcomes in relation to blood pressure in a number of ways.:
1) Blood pressure reached -trials will be analysed in groups based on the mean systolic blood pressure achieved in the intervention group. The different groups will preliminarily be those <130, <135 and <140.
2) Baseline pressure -trials will be grouped according to baseline systolic pressure in the intervention group. The preliminary groups will be those <130, <140 and <150.
3) Meta regression, correlating relative risk, for a number of outcomes, and systolic blood pressure difference between groups, will be performed if suitable.
Sensitivity-analysis will be performed, excluding patients with manifest cardiovascular disease, such as earlier myocardial infarction or stroke and diagnosed congestive heart failure. Also the impact of trials with high risk of bias, and trials stopped early will be explored in this way. We will also try to analyse data stratified according to mortality rate in the placebo group to assess if a certain cardiovascular risk justifies other treatment regimen.
Heterogeneity will be considered using forest plot and standard statistic methods such as chi-squared test and quantifying inconsistency. If there is evidence of heterogeneity analyses will be performed using random effects models. Possible causes of heterogeneity will be explored. Reporting bias will be assessed using funnel plots and contour enhanced funnel plots. Forest plot showing relative risk of myocardial infarction in meta-analysis. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analysis (bottom). Isquared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity.
Search strategies
Forest plot showing relative risk of stroke in meta-analysis. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analysis (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity.
Forest plot showing relative risk of heart failure in meta-analysis. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analysis (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity.
Forest plot showing relative risk of end-stage renal disease in meta-analysis. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analysis (bottom). Isquared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity.
Forest plots showing relative risk of amputation and blindness in meta-analyses. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analysis (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Forest plot showing relative risk of all-cause mortality in meta-analysis, stratified by baseline systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of cardiovascular mortality in meta-analysis, stratified by baseline systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of myocardial infarction in meta-analysis, stratified by baseline systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of stroke in meta-analysis, stratified by baseline systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of heart failure in meta-analysis, stratified by baseline systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of end-stage renal disease (ESRD) in meta-analysis, stratified by baseline systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the metaanalyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom). Forest plot showing relative risk of all-cause mortality in meta-analysis, stratified by attained systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of cardiovascular mortality in meta-analysis, stratified by attained systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of myocardial infarction in meta-analysis, stratified by attained systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of stroke in meta-analysis, stratified by attained systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of heart failure in meta-analysis, stratified by attained systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the meta-analyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom).
Forest plot showing relative risk of end-stage renal disease (ESRD) in meta-analysis, stratified by attained systolic blood pressure (SBP), excluding trials including predominantly patients with heart failure. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the meta-analysis. Blue diamonds represent the results from the metaanalyses for each blood pressure strata, and for all strata combined (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity. Heterogeneity is measured for each stratum separately, and for all strata combined (bottom). e) Attained SBP -summary Forest plot showing relative risk of cardiovascular mortality in meta-analysis of trials with baseline systolic blood pressure, excluding ALTITUDE. Black dots represent relative risk in each trial, black lines represent confidence intervals (CI) in each trial, and grey squares represent the weight given each trial in the metaanalysis. Blue diamonds represent the results from the meta-analysis (bottom). I-squared is a measure of heterogeneity, and the following p-value represents the significance of that heterogeneity.
Risk of bias
Risk of bias was generally considered low or unclear across domains. The most common reason for judging unclear risk of bias was lack of reporting. High risk of bias was present in at least one domain in 19 of 49 trials. The most common reasons for judging high risk of bias was that trials were stopped early because of treatment effects, that they were confined to heart failure patients with anticipated treatment effect besides that of BP lowering, or that sponsors were involved in the design of the trial, interpretation of the results, and writing of the report. All these concerns are represented in the domain other sources of bias, and was present in twelve trials in total. Trials confined to heart failure patients were excluded from the stratified analyses. Trials stopped early and trials subject to sponsor involvement were mostly trials in the higher BP range, hence potentially overestimating the effect in these strata, but not affecting low BP analyses. Selective reporting was suspected in six trials. This was a combination of outcomes specified in the study protocol, but not being reported in the publication, and outcomes being reported in ways that could not be included in the meta-analyses. Because this problem was present in only about one tenth of all studies, and it was spread across different outcomes, it was not judged to affect the overall results. We found one study, judged to have high risk of bias on three domains (DIRECT-P2), with potential for detection bias, attrition bias and reporting bias. Excluding this trial from the analyses shifted the point estimate and confidence intervals for CV mortality and myocardial infarction slightly more towards harm in the stratified analyses with baseline SBP < 140 mm Hg.
Funnel plots were made for all trials combined for each outcome studied, and for mortality in each SBP strata (web appendix). The overall plots for all-cause mortality and myocardial infarction showed potential asymmetry, judged by visual inspection. However, this could be explained by expected differences in treatment effect in different SBP strata, and was not present in stratified analyses. Also, asymmetry was non-significant using Egger´s and Begg´s tests.
a) Summary graph across domains
Green dots represent low risk of bias. Yellow dots represent unclear risk of bias. Red dots represent high risk of bias. In the other bias category we systematically judged if trials were stopped early, if there were extensive sponsor involvement, if there were major changes to the protocol, and if there were clinically significant baseline imbalances between groups. SE = standard error, RR = relative risk, log indicates logarithmic scale. Each dot represents one trial.
